全文获取类型
收费全文 | 3057篇 |
免费 | 205篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 53篇 |
儿科学 | 84篇 |
妇产科学 | 32篇 |
基础医学 | 359篇 |
口腔科学 | 78篇 |
临床医学 | 318篇 |
内科学 | 639篇 |
皮肤病学 | 58篇 |
神经病学 | 283篇 |
特种医学 | 127篇 |
外科学 | 566篇 |
综合类 | 16篇 |
一般理论 | 3篇 |
预防医学 | 199篇 |
眼科学 | 69篇 |
药学 | 179篇 |
中国医学 | 2篇 |
肿瘤学 | 209篇 |
出版年
2023年 | 20篇 |
2022年 | 35篇 |
2021年 | 81篇 |
2020年 | 57篇 |
2019年 | 91篇 |
2018年 | 100篇 |
2017年 | 81篇 |
2016年 | 91篇 |
2015年 | 90篇 |
2014年 | 112篇 |
2013年 | 178篇 |
2012年 | 222篇 |
2011年 | 269篇 |
2010年 | 161篇 |
2009年 | 127篇 |
2008年 | 187篇 |
2007年 | 189篇 |
2006年 | 191篇 |
2005年 | 196篇 |
2004年 | 172篇 |
2003年 | 141篇 |
2002年 | 137篇 |
2001年 | 32篇 |
2000年 | 28篇 |
1999年 | 31篇 |
1998年 | 25篇 |
1997年 | 23篇 |
1996年 | 9篇 |
1995年 | 12篇 |
1994年 | 14篇 |
1993年 | 16篇 |
1992年 | 10篇 |
1991年 | 11篇 |
1989年 | 10篇 |
1988年 | 10篇 |
1987年 | 9篇 |
1985年 | 4篇 |
1984年 | 6篇 |
1983年 | 6篇 |
1982年 | 4篇 |
1979年 | 6篇 |
1978年 | 4篇 |
1976年 | 6篇 |
1975年 | 5篇 |
1970年 | 7篇 |
1969年 | 4篇 |
1968年 | 4篇 |
1967年 | 4篇 |
1966年 | 6篇 |
1965年 | 4篇 |
排序方式: 共有3274条查询结果,搜索用时 31 毫秒
51.
Olga Amaral Ana Marcão Eugénia Pinto Ari Zimran M.C.Sá Miranda 《Blood cells, molecules & diseases》1997,23(3):415-416
ABSTRACT: A new polymorphism, in intron 7 of glucocerebrosidase gene, has been identified in Gaucher Disease patients. It seems to appear only in Pv1.1-alleles bearing the N370S mutation. This new sub-haplotype was only identified in Portuguese patients, of origins spanning all of the Portuguese continental territory. This finding indicates that, in the Portuguese, mutation N370S has existed in the context of two slightly different haplotypes and thus must be relatively ancient. 相似文献
52.
Bitnun A Sochett E Dick PT To T Jefferies C Babyn P Forbes J Read S King SM 《The Journal of clinical endocrinology and metabolism》2005,90(1):168-174
Previous pediatric studies have failed to demonstrate a clear association between protease inhibitor (PI) therapy and abnormal glucose homeostasis in HIV-infected children. To define more precisely the impact of PI therapy on glucose homeostasis in this population, we performed the insulin-modified frequent-sampling iv glucose tolerance test on 33 PI-treated and 15 PI-naive HIV-infected children. Other investigations included fasting serum lipids; glucose, insulin, and C-peptide; single-slice abdominal computed tomography; and, in a subset of PI-treated children, an oral glucose tolerance test.There were no differences between the two groups with respect to fasting serum insulin or C-peptide, homeostatic model assessment insulin resistance, or quantitative insulin sensitivity check index. The mean insulin sensitivity index of PI-treated and PI-naive children was 6.93 +/- 6.37 and 10.58 +/- 12.93 x 10(-4)min(-1) [microU/ml](-1), respectively (P = 0.17). The mean disposition index for the two groups was 1840 +/- 1575 and 3708 +/- 3005 x 10(-4)min(-1) (P = 0.013), respectively. After adjusting for potential confounding variables using multiple regression analysis, the insulin sensitivity index and disposition index of PI-treated children were significantly lower than that of PI-naive children (P = 0.01 for both). In PI-treated but not PI-naive children, insulin sensitivity correlated inversely with visceral adipose tissue area (r = -0.43, P = 0.01) and visceral to sc adipose tissue ratio (r = -0.49, P = 0.004). Mildly impaired glucose tolerance was noted in four of 21 PI-treated subjects tested.Our results demonstrate not only that PI therapy reduces insulin sensitivity in HIV-infected children but also that it impairs the beta-cell response to this reduction in insulin sensitivity and, in a subset of children, leads to the development of impaired glucose tolerance. The presence of insulin resistance, dyslipidemia, and the significant correlation of reduced insulin sensitivity with increased visceral adipose tissue content suggest that PI-containing highly active antiretroviral therapy is associated with the emergence of early features of a metabolic syndrome-like phenotype. 相似文献
53.
54.
55.
To assess risk factors related to the development of chronic obstructive pulmonary disease (COPD) including smoking and occupational exposure (OE) to dusts, gases or fumes, we performed a longitudinal 11-year follow-up postal survey. The original study population was a random population sample of 8000 inhabitants of Helsinki aged 20 to 69 years in 1996. Participants of the first postal questionnaire were invited to this follow-up survey in 2007 with 4302 (78%) answers obtained. Cumulative incidence of COPD in 11 years was 3.43% corresponding to an incidence rate of 3.17/1000/year after exclusion of those with self-reported physician-diagnosed COPD and ever COPD in 1996. Smoking and age, but not gender, were associated with incident COPD. Reported family history of COPD increased the cumulative incidence to 8.55% vs 3.04% among those without a family history (p < 0.001). In multivariate analysis, significant independent risk factors for incident COPD were: current smoking in 1996 (OR 4.40 [95% CI 2.89–6.71]), age over 50 (OR 3.42 [95% CI 2.22–5.26]), family history of COPD (OR 2.08 [1.27–3.43]), ever asthma (OR 2.28 [1.35–3.86]), and self-reported OE (OR 2.14 [1.50–3.05]). Occupational exposure to dusts, gases or fumes, assessed both based on self-reported exposure and a job exposure matrix using reported professions, was an independent risk factor for incident COPD. Smoking and OE together yielded an additive effect on incidence of COPD. 相似文献
56.
57.
Kari J Kurppa Javier Catón Peter R Morgan Ari Ristimäki Blandine Ruhin Jari Kellokoski Kristiina Heikinheimo 《The Journal of pathology》2014,232(5):492-498
Ameloblastoma is a benign but locally infiltrative odontogenic neoplasm. Although ameloblastomas rarely metastasise, recurrences together with radical surgery often result in facial deformity and significant morbidity. Development of non‐invasive therapies has been precluded by a lack of understanding of the molecular background of ameloblastoma pathogenesis. When addressing the role of ERBB receptors as potential new targets for ameloblastoma, we discovered significant EGFR over‐expression in clinical samples using real‐time RT–PCR, but observed variable sensitivity of novel primary ameloblastoma cells to EGFR‐targeted drugs in vitro. In the quest for mutations downstream of EGFR that could explain this apparent discrepancy, Sanger sequencing revealed an oncogenic BRAF V600E mutation in the cell line resistant to EGFR inhibition. Further analysis of the clinical samples by Sanger sequencing and BRAF V600E‐specific immunohistochemistry demonstrated a high frequency of BRAF V600E mutations (15 of 24 samples, 63%). These data provide novel insight into the poorly understood molecular pathogenesis of ameloblastoma and offer a rationale to test drugs targeting EGFR or mutant BRAF as novel therapies for ameloblastoma. Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk 相似文献
58.
Toni Urbanik Bruno Christian Koehler Laura Wolpert Christin El?ner Anna-Lena Scherr Thomas Longerich Nicole Kautz Stefan Welte Nadine H?velmeyer Dirk J?ger Ari Waisman Henning Schulze-Bergkamen 《World journal of gastroenterology : WJG》2014,20(45):17049-17064
AIM:To analyze the role of CYLD for receptor-mediated cell death of murine hepatocytes in acute liver injury models.METHODS:Hepatocyte cell death in CYLD knockout mice(CYLD-/-)was analyzed by application of liver injury models for CD95-(Jo2)and tumor necrosis factor(TNF)-α-[D-Gal N/lipopolysaccharide(LPS)]induced apoptosis.Liver injury was assessed by measurement of serum transaminases and histological analysis.Apoptosis induction was quantified by cleaved PARP staining and Western blotting of activated caspases.Nuclear factor(NF)-κB,ERK,Akt and jun amino-terminal kinases signaling were assessed.Primary Hepatocytes were isolated by two step-collagenase perfusion and treated with recombinant TNF-αand with the CD95-ligand Jo2.Cell viability was analyzed by MTT-assay.RESULTS:Livers of CYLD-/-mice showed increased anti-apoptotic NF-κB signaling.In both applied liver injury models CYLD-/-mice showed a significantly reduced apoptosis sensitivity.After D-Gal N/LPS treatment CYLD-/-mice exhibited significantly lower levels of alanine aminotransferase(ALT)(295 U/L vs 859 U/L,P<0.05)and aspartate aminotransferase(AST)(560 U/L vs 1025 U/L,P<0.01).After Jo injection CYLD-/-mice showed 2-fold lower ALT(50 U/L vs 110 U/L,P<0.01)and lower AST(250 U/L vs 435 U/L,P<0.01)serumlevels compared to WT mice.In addition,isolated CYLD-/-primary murine hepatocytes(PMH)were less sensitive towards death receptor-mediated apoptosis and showed increased levels of Bcl-2,XIAP,c IAP1/2,survivin and c-FLIP expression upon TNF-and CD95-receptor triggering,respectively.Inhibition of NF-κB activation by the inhibitor of NF-κB phosphorylation inhibitor BAY 11-7085 inhibited the expression of antiapoptotic proteins and re-sensitized CYLD-/-PMH towards TNF-and CD95-receptor mediated cell death.CONCLUSION:CYLD is a central regulator of apoptotic cell death in murine hepatocytes by controlling NF-κB dependent anti-apoptotic signaling. 相似文献
59.
Andrea Franceschini Roger Meier Alain Casanova Saskia Kreibich Neha Daga Daniel Andritschke Sabrina Dilling Pauli R?m? Mario Emmenlauer Andreas Kaufmann Raquel Conde-álvarez Shyan Huey Low Lucas Pelkmans Ari Helenius Wolf-Dietrich Hardt Christoph Dehio Christian von Mering 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(12):4548-4553
60.
Fausto Biancari Tomas Gudbjartsson Jouni Heikkinen Vesa Anttila Timo Mäkikallio Anders Jeppsson Linda Thimour-Bergström Carmelo Mignosa Antonino S. Rubino Kari Kuttila Jarmo Gunn Jan-Ola Wistbacka Kari Teittinen Kari Korpilahti Francesco Onorati Giuseppe Faggian Giulia Vinco Corrado Vassanelli Flavio Ribichini Tatu Juvonen Tomas A. Axelsson Axel F. Sigurdsson Pasi P. Karjalainen Ari Mennander Olli Kajander Markku Eskola Erkki Ilveskoski Veronica D'Oria Marisa De Feo Tuomas Kiviniemi K.E. Juhani Airaksinen 《The American journal of cardiology》2014